Neurotransmitter receptor transport

Across TCGA pan-cancer cohorts, RNA activity of the Neurotransmitter receptor transport pathway differs between tumor and matched normal tissue in 12 of the 18 cancer types tested.

The strongest signal is observed in lung adenocarcinoma (LUAD), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUAD and LUSC, show the opposite pattern, with lower activity in tumor tissue.

LUAD, LUSC, and STAD show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LUAD	Female	All	−0.202	<.001	9	view →
LUSC	Female	II,III,IV	−0.250	<.001	8	view →
STAD	All	All	+0.064	<.001	6	view →
BRCA	All	All	+0.028	<.001	6	view →
KIRC	All	All	+0.031	<.001	5	view →
THCA	All	All	−0.029	<.001	5	view →
COAD	Female	All	−0.042	<.001	4	view →
KIRP	Female	II,III,IV	+0.054	.017	3	view →
CHOL	All	All	+0.060	.003	2	view →
HNSC	Female	III,IV	−0.037	.033	2	view →
KICH	All	All	+0.028	.021	2	view →
LIHC	All	All	+0.023	.003	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 12 lineages.

GO:0099637–LUAD

Open the LUAD breakdown →